THESEUS PHARMACEUTICALS INC's ticker is and the CUSIP is 88369M101. A total of 73 filers reported holding THESEUS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21 | -72.7% | 7,832 | -6.4% | 0.00% | – |
| Q2 2023 | $77 | -33.0% | 8,365 | -35.6% | 0.00% | – |
| Q1 2023 | $115 | +161.4% | 12,993 | +45.9% | 0.00% | – |
| Q4 2022 | $44 | -99.8% | 8,904 | +76.0% | 0.00% | – |
| Q3 2022 | $29,000 | 0.0% | 5,060 | -2.5% | 0.00% | – |
| Q2 2022 | $29,000 | -59.7% | 5,192 | -16.4% | 0.00% | – |
| Q1 2022 | $72,000 | – | 6,210 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 4,108,796 | $11,052,661 | 17.63% |
| Omega Fund Management, LLC | 711,479 | $1,913,879 | 1.76% |
| Lynx1 Capital Management LP | 702,415 | $1,889,496 | 1.25% |
| Orbimed Advisors | 17,713,600 | $47,649,584 | 1.01% |
| Nextech Invest Ltd. | 611,310 | $1,644,424 | 0.50% |
| Frazier Life Sciences Management, L.P. | 2,248,194 | $6,047,642 | 0.40% |
| Affinity Asset Advisors, LLC | 400,726 | $1,077,953 | 0.30% |
| DENALI ADVISORS LLC | 127,900 | $344,051 | 0.12% |
| Rock Springs Capital Management LP | 437,329 | $1,176,415 | 0.03% |
| Forefront Analytics, LLC | 17,672 | $47,539 | 0.03% |